IgA nephropathy trials in United States

In United States 26 Also abroad 92

26 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Where
Cincinnati, Memphis, Neptune City, Oklahoma City
Age
2 years to 18 years
People
28 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07498335
Phase 3Taking people
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Where
Albuquerque, Arlington, Birmingham, Boise, Chicago, Cincinnati, City of Saint Peters, Columbus, Dallas, East Point, East Providence, Edina, El Paso, Fremont, Houston, Jacksonville, Kansas City, Katy, Lansing, Lauderdale Lakes, Los Angeles, Media, Melbourne, Miami, Montgomery, Morgantown, Orange, Orlando, Pembroke Pines, Philadelphia, Pontiac, Riverview, Rockford, Saint Joseph, Salt Lake City, San Antonio, Sanford, San Francisco, Shreveport, Surprise, Winston-Salem
Age
18 years and over
People
347 worldwide
Run by
Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00
Phase 3Taking people
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Where
Arvada, Atlanta, Katy, Lauderdale Lakes
Age
18 years and over
People
480
Run by
Jade Biosciences, Inc.
See details and how to joinNCT07902817 · EU 2026-527177-11-00
Phase 2Taking people
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Where
Arvada, Chula Vista, Denver, Houston, Orlando, Pembroke Pines
Age
18 years to 60 years
People
30 worldwide
Run by
Jade Biosciences, Inc.
See details and how to joinNCT07541287
Phase 2Taking people
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Where
Houston, Manassas, Miami, Pembroke Pines, Pontiac, Salt Lake City, Valencia
Age
18 years and over
People
120 worldwide
Run by
argenx
See details and how to joinNCT07773727 · EU 2026-525638-43-00
Phase 2Taking people
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Where
Acworth, Denver, Edina, Iowa City, San Francisco
Age
18 years and over
People
32 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00
Phase 2Taking people
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Where
Columbus, Dakota Dunes, Dallas, Doral, Great Neck, Houston, Iowa City, Miami, Pembroke Pines, Shelby, Shreveport
Age
18 years and over
People
45 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06989359
Phase 3Enrolling by invitation
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Where
Arvada, Houston, Idaho Falls, Orlando
Age
18 years and over
People
605
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT07807995 · EU 2025-525064-14-00
Phase 3Taking people
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Where
Acworth, Apple Valley, Boston, Bradenton, Brookhaven, Carlsbad, City of Saint Peters, Dallas, Detroit, Gainesville, Garden Grove, Hollywood, Houston, Katy, Knoxville, Little Rock, Los Angeles, Milwaukee, New York, Orlando, Oxnard, Philadelphia, Pontiac, Port Saint Lucie, Providence, San Dimas, The Bronx, Worcester
Age
18 years and over
People
454 worldwide
Run by
Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00
Phase 2Taking people
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Where
Jacksonville, Rochester
Age
18 years and over
People
16
Run by
Mayo Clinic
See details and how to joinNCT06676579
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Aurora, Baltimore, Boston, Chubbuck, Dallas, Glendale, Hinsdale, Houston, Jersey City, Kansas City, Las Vegas, Newark, New York, Rochester, San Diego, San Dimas
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
Phase 2Taking people
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Where
Hollywood, Lawrenceville, Orangeburg
Age
16 years and over
People
30 worldwide
Run by
Akebia Therapeutics
See details and how to joinNCT06419205
Phase 4Not yet taking people in United States
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
Where
Chicago
Age
18 years and over
People
20
Run by
University of Illinois Chicago
See details and how to joinNCT07820995
Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Where
Aurora, Gainesville, Madera, Philadelphia, Salt Lake City
Age
2 years to 18 years
People
31 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06994845
Phase 1/2Taking people
PS-002 for the Treatment of IgA Nephropathy in Adults
Where
Baltimore, Miami
Age
18 years and over
People
32 worldwide
Run by
Purespring Therapeutics Limited
See details and how to joinNCT07182227 · EU 2025-523201-14-00
Phase 3Taking people
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Where
Brentwood, Clifton Park, Dallas, Denver, Houston, Iowa City, New York, Orlando
Age
18 years to 100 years
People
220 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06858319
Phase 2Taking people
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Where
Atlanta, Dakota Dunes, Denver, Hinsdale, Houston, Los Angeles, San Antonio, Tamarac
Age
18 years to 75 years
People
96 worldwide
Run by
Walden Biosciences
See details and how to joinNCT06466135
Phase 3Taking people
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Where
Aurora, Palo Alto
Age
2 years to 18 years
People
36 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00
Phase 2Taking people
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Where
Birmingham, Chubbuck, Cleveland, Columbus, Houston, Las Vegas, Lawrenceville, Los Angeles, Orlando
Age
18 years to 99 years
People
20 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06797518
Phase 2Taking people
Atacicept in Multiple Glomerular Diseases
Where
Brisbane
Age
2 years and over
People
250
Run by
Vera Therapeutics, Inc.
See details and how to joinNCT06983028
Phase 1Taking people
Study of BHV-1400 in IgA Nephropathy
Where
Chesterfield, Dakota Dunes, Farmington, Hinsdale, Houston, Indianapolis, Lawrenceville, Miami Lakes, Orlando, Pembroke Pines, Salt Lake City, Shelby
Age
18 years to 65 years
People
20 worldwide
Run by
Biohaven Therapeutics Ltd.
See details and how to joinNCT07054684
Phase 2Enrolling by invitation
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Where
Brisbane
Age
18 years to 99 years
People
750
Run by
Vera Therapeutics, Inc.
See details and how to joinNCT06674577
Phase 2Taking people
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Where
Ann Arbor, Boston, Chapel Hill, Charlotte, Columbus, Durham, Hackensack, Houston, Iowa City, Kansas City, Los Angeles, Miami, Minneapolis, Neptune City, New Hyde Park, New York, Oklahoma City, Philadelphia, Seattle, Wilmington
Age
1 year to 17 years
People
67 worldwide
Run by
Travere Therapeutics, Inc.
See details and how to joinNCT05003986 · EU 2023-505497-14-00
Phase 2/3Enrolling by invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Where
Atlanta, Birmingham, Boston, Columbus, Dakota Dunes, Denver, Great Neck, Houston, Lauderdale Lakes, Lawrenceville, Los Angeles, Milwaukee, Palo Alto, Shelby, Worcester
Age
18 years and over
People
600 worldwide
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659
No phaseTaking people
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Where
Boston
Age
18 years and over
People
300
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06952426